fbpx
CAS Insight

molecules of the month

BMS-820132

oral GK partial activator

Ph. I candidate for diabetes

from HTS of BMS collection and SBDD

J. Med. Chem.

Bristol Myers Squibb

oral GK partial activator - Bristol Myers Squibb
4 mins read

Context.BMS-820132 (Bristol Myers Squibb) is an oral glucokinase (GK) partial activator intended for diabetes. GK activators for diabetes were hotly pursued in the late 2000’s, with well over 100 industry patents on GK activators by 2009. The pursuit was triggered by the discovery of the first allosteric activators of glucokinase from an enzymatic screen of 120k compounds at Roche in 2003, leading to the first GK activator studied in diabetes patients. Initial clinical glucokinase full activators were challenged by hypoglycemia and loss of efficacy over time, leading to alternative strategies such as hepatoselective molecules, and the partial activation approach employed here. Target. Unlike protein kinases, glucokinase (GK, hexokinase IV) phosphorylates glucose to glucose-6-phosphate. GK is not saturated at physiological glucose…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: